Restrictive Intraoperative Fluid Rate is Associated with Improved Outcomes in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

被引:5
|
作者
Peng, June S. [1 ,2 ]
LaPiano, Jessica [3 ]
Wang, Katy [4 ]
Attwood, Kristopher [4 ]
Skitzki, Joseph J. [5 ]
Kane, John M., III [1 ]
Francescutti, Valerie A. [1 ,5 ]
机构
[1] Roswell Pk Comprehens Canc Ctr, Dept Surg Oncol, Buffalo, NY 14203 USA
[2] Penn State Univ, Div Surg Oncol, Coll Med, Dept Surg, Hershey, PA 16801 USA
[3] Univ Buffalo, Jacobs Sch Med & Biomed Sci, Buffalo, NY USA
[4] Roswell Pk Comprehens Canc Ctr, Dept Biostat & Bioinformat, Buffalo, NY USA
[5] McMaster Univ, Dept Surg, Hamilton, ON, Canada
关键词
MORBIDITY; THERAPY; TRIAL;
D O I
10.1245/s10434-021-10556-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Management of patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CS/HIPEC) has historically favored liberal fluid administration owing to lengthy duration of surgery and hyperthermia. This practice has been challenged in recent years with studies demonstrating improved outcomes with restrictive fluid administration. Methods Patients who underwent CS/HIPEC between March 2010 and September 2018 were included for analysis. Patients who received an above-median fluid rate (high-IVF) versus below-median fluid rate (low-IVF) were compared, and multivariate analyses were performed for length of stay, 90-day unplanned readmissions, and major complications. Results The 167 patients had a mean age of 56.7 +/- 11.4 years and body mass index of 29.5 +/- 6.9 kg/m(2). The median rate of total intraoperative crystalloid and colloid was 7.4 mL/kg/h. The low-IVF group had less blood loss (183 vs. 330 mL, p = 0.002), were less likely to need intraoperative vasopressor drip (2.4% vs. 11.9%, p = 0.018), and experienced fewer cardiac complications (2.4% vs. 10.7%, p = 0.031), pneumonias (0% vs. 6.0%, p = 0.024), and Clavien-Dindo grade 3-5 complications (14.5% vs. 33.3%, p = 0.004). Multivariate analyses identified bowel resection (HR 4.65, p = 0.0008) as a risk factor for 90-day unplanned readmission, while bowel resection, intraoperative fluid rate, and estimated blood loss were associated with increased length of stay. Conclusion Higher intraoperative fluid intake was associated with multiple postoperative complications and increased length of stay, and represents a potentially avoidable risk factor for morbidity in CS/HIPEC.
引用
收藏
页码:163 / 173
页数:11
相关论文
共 50 条
  • [21] Inflammatory response and optimalisation of perioperative fluid administration during hyperthermic intraoperative intraperitoneal chemotherapy surgery
    de Witte, Piet
    de Witt, Christien A.
    van de Minkelis, Johan L.
    Boerma, Djamila
    Solinger, H. Frank
    Hack, C. Erik
    Bruins, Peter
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2019, 10 (02) : 244 - 253
  • [22] Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy, Part II: Implementation
    Dunn, Debra
    Ciccarelli, Eileen
    Moltzen, Nina
    AORN JOURNAL, 2019, 110 (06) : 606 - 625
  • [23] Complications and Toxicities After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    Canda, Aras Emre
    Sokmen, Selman
    Terzi, Cem
    Arslan, Cigdem
    Oztop, Ilhan
    Karabulut, Bulent
    Ozzeybek, Deniz
    Sarioglu, Sulen
    Fuzun, Mehmet
    ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (04) : 1082 - 1087
  • [24] Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy in Elderly Patients
    Macri, Antonio
    Saladino, Edoardo
    Trimarchi, Giuseppe
    Bartolo, Vincenzo
    Rossitto, Maurizio
    Cannao, Antonio
    Rizzo, Antongiacomo
    Famulari, Ciro
    IN VIVO, 2011, 25 (04): : 687 - 690
  • [25] Impact of Distal Pancreatectomy on Outcomes of Peritoneal Surface Disease Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    Doud, AndreaN.
    Randle, Reese W.
    Clark, Clancy J.
    Levine, Edward A.
    Swett, Katrina R.
    Shen, Perry
    Stewart, John H.
    Votanopoulos, Konstantinos I.
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (05) : 1645 - 1650
  • [26] The Hemodynamic Management and Postoperative Outcomes After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Prospective Observational Study
    Solanki, Sohan Lal
    Agarwal, Vandana
    Ambulkar, Reshma P.
    Joshi, Malini P.
    Chawathey, Shreyas
    Rudrappa, Shivacharan Patel
    Bhandare, Manish
    Saklani, Avanish P.
    CRITICAL CARE RESEARCH AND PRACTICE, 2024, 2024 (01)
  • [27] Anesthetic concerns during cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
    Ryu, Jung-Hee
    Koo, Chang-Hoon
    KOREAN JOURNAL OF ANESTHESIOLOGY, 2021, 74 (02) : 89 - 90
  • [28] Anesthetic management of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy procedures
    Davide Corbella
    Emanuele Piraccini
    Paolo Finazzi
    Pietro Brambillasca
    Viviana Prussiani
    Massimo Ruggero Corso
    Claudio Germandi
    Vanni Agnoletti
    World Journal of Obstetrics and Gynecology, 2013, (04) : 129 - 136
  • [29] Hematological Alterations after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    Pintado, Maria Consuelo
    Unzue, Inmaculada Lasa
    Sanz, Remedios Gomez
    Alonso, Manuel Diez
    Ortega, Miguel A.
    de Mon, Melchor Alvarez
    Losada, Emilio Nevado
    Calvo, Alberto Gutierrez
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (13)
  • [30] "Natural history" of complete cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
    Elias, D.
    Di Pietrantonio, D.
    Boulet, T.
    Honore, C.
    Bonnet, S.
    Goere, D.
    Kohneh-Shahri, N.
    Raynard, B.
    EJSO, 2009, 35 (04): : 434 - 438